Jean-Ehrland RICCI
jer-06.bsky.social
Jean-Ehrland RICCI
@jer-06.bsky.social
INSERM research director & metabolism-lover, studying metabolism in cancer & immunity, Nice, France.
Editor-in-Chief of Oncogenesis www.nature.com/oncsis
#cancermetabolism #immunometabolism #mitophagy #CAR-T - www.c3m-nice.fr/en/Teams/team-03/
Reposted by Jean-Ehrland RICCI
Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.
November 13, 2025 at 8:40 AM
Reposted by Jean-Ehrland RICCI
Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.
November 11, 2025 at 10:41 AM
Reposted by Jean-Ehrland RICCI
Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.
November 7, 2025 at 9:53 AM
Reposted by Jean-Ehrland RICCI
Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.
November 4, 2025 at 8:02 AM
Reposted by Jean-Ehrland RICCI
Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.
October 30, 2025 at 8:19 AM
Reposted by Jean-Ehrland RICCI
Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
October 27, 2025 at 2:35 PM
Reposted by Jean-Ehrland RICCI
📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀
October 27, 2025 at 2:29 PM
Reposted by Jean-Ehrland RICCI
Romain RISCAL (IRCM - Institut de Recherche en Cancérologie de Montpellier) et Eric Solary (Gustave Roussy, Vice‑président de la Fondation ARC pour la recherche sur le cancer).
October 22, 2025 at 9:18 AM
Reposted by Jean-Ehrland RICCI
Jacqueline Lehmann-Che (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Paris), Camille Lobry (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Thomas Mercher ( @gustaveroussy.fr
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)
October 22, 2025 at 9:18 AM
Reposted by Jean-Ehrland RICCI
Check the working model the author propose where HOTAIR serves as a scaffold enhancing the interaction between MEST and super-enhancers, increasing MEST expression, promoting glioblastoma cell proliferation and invasive migration, and ultimately contributing to tumor progression.
October 16, 2025 at 9:19 AM
Reposted by Jean-Ehrland RICCI
Check how this study underscored the significant role of glycoRNAs in glioma proliferation and provided a foundation for further research into their potential as novel biomarkers and therapeutic targets for glioma.
October 14, 2025 at 7:11 AM
Reposted by Jean-Ehrland RICCI
In my role as AE for Oncogenesis, I look for translation potential and solid experimental work in a manuscript. I believe such studies are key to advancing science as well as cancer care.

–Maarten

Delighted to have him on our team at #Oncogenesis! 🤝
October 9, 2025 at 8:58 AM
Reposted by Jean-Ehrland RICCI
But also aim to ascertain efficacy from novel interventions or stratification modalities in early phase clinical studies.
October 9, 2025 at 8:57 AM